Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
Clinical trial NCT05400070 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05400070
- Sponsor
- Tang-Du Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-01
- Primary completion
- 2023-12-30
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.